{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044017","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.182677+00:00","generated_at":"2026-05-30T04:09:29.803052+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProPhase Labs proposes public stock offering; discloses $500K term note and future receipts deals","bullets":["Announced underwritten public offering of common stock and/or pre-funded warrants; no size or price disclosed.","ThinkEquity sole book-running manager; proceeds earmarked for working capital, product development, and M&A.","Disclosed $500K term note at 15% interest and two future receipts financings aggregating ~$2.1M.","BE-Smart esophageal cancer test faces regulatory uncertainty due to new FDA LDT rule."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044017","json":"https://secwatch.observer/filing/0001493152-24-044017.json","markdown":"https://secwatch.observer/filing/0001493152-24-044017.md","text":"https://secwatch.observer/filing/0001493152-24-044017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224044017/0001493152-24-044017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224044017/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:09:29.803052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}